Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HP184 in Chronic Spinal Cord Injury
NCT00093275Phase 2Completed
- Sponsor
- Sanofi
- Start
- Oct 2004
- Primary completion
- Dec 2005
- Modality
- Multivalent & Scaffold-Based Small Molecules, Classical Binding Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial in chronic spinal cord injury (SCI) comparing HP184 with Placebo (2 arms). Primary endpoint: Change from baseline in total motor score of American Spinal Injury Association (ASIA) manual motor test at 24 weeks. Started Oct 2004; status: completed.
02
Drugs
nerispirdine
03
Conditions
chronic spinal cord injury (SCI)
Beyond the preview
Go deeper on NCT00093275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00093275.